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ARTICLE OPEN
The clinical impact of copy number variants in inherited bone
marrow failure syndromes
Nicolas Waespe 1,2, Santhosh Dhanraj1,3, Manju Wahala1, Elena Tsangaris1, Tom Enbar1, Bozana Zlateska1,3, Hongbing Li1,
Robert J. Klaassen4, Conrad V. Fernandez5, Geoff D. E. Cuvelier6, John K. Wu7, Yves D. Pastore8, Mariana Silva9, Jeffrey H. Lipton10,
Joseé Brossard11, Bruno Michon12, Sharon Abish13, MacGregor Steele14, Roona Sinha15, Mark J. Belletrutti16, Vicky R. Breakey17,
Lawrence Jardine18, Lisa Goodyear19, Liat Koﬂer1, Michaela Cada3, Lillian Sung20, Mary Shago21, Stephen W. Scherer1 and Yigal Dror1,2,3
Inherited bone marrow failure syndromes comprise a genetically heterogeneous group of diseases with hematopoietic failure and a
wide array of physical malformations. Copy number variants were reported in some inherited bone marrow failure syndromes. It is
unclear what impact copy number variants play in patients evaluated for a suspected diagnosis of inherited bone marrow failure
syndromes. Clinical and genetic data of 323 patients from the Canadian Inherited Marrow Failure Registry from 2001 to 2014, who
had a documented genetic work-up, were analyzed. Cases with pathogenic copy number variants (at least 1 kilobasepairs) were
compared to cases with other mutations. Genotype-phenotype correlations were performed to assess the impact of copy number
variants. Pathogenic nucleotide-level mutations were found in 157 of 303 tested patients (51.8%). Genome-wide copy number
variant analysis by single-nucleotide polymorphism arrays or comparative genomic hybridization arrays revealed pathogenic copy
number variants in 11 of 67 patients tested (16.4%). In four of these patients, identiﬁcation of copy number variant was crucial for
establishing the correct diagnosis as their clinical presentation was ambiguous. Eight additional patients were identiﬁed to harbor
pathogenic copy number variants by other methods. Of the 19 patients with pathogenic copy number variants, four had
compound-heterozygosity of a copy number variant with a nucleotide-level mutation. Pathogenic copy number variants were
associated with more extensive non-hematological organ system involvement (p = 0.0006), developmental delay (p = 0.006) and
short stature (p = 0.04) compared to nucleotide-level mutations. In conclusion, a signiﬁcant proportion of patients with inherited
bone marrow failure syndromes harbor pathogenic copy number variants which were associated with a more extensive non-
hematological phenotype in this cohort. Patients with a phenotype suggestive of inherited bone marrow failure syndromes but
without identiﬁcation of pathogenic nucleotide-level mutations should undergo speciﬁc testing for copy number variants.
npj Genomic Medicine  (2017) 2:18 ; doi:10.1038/s41525-017-0019-2
INTRODUCTION
Inherited bone marrow failure syndromes (IBMFSs) are complex
genetic disorders characterized by hematopoietic failure, which
results in single or multi-lineage cytopenias, and an increased
prevalence of physical malformations.1–3 A wide variety of speciﬁc
syndromes have been described so far with more than 80
different genes associated to IBMFSs. These include genes
involved in ribosome biogenesis that are associated with
Diamond–Blackfan anemia4 and Shwachman-Diamond syn-
drome,5 genes involved in telomere maintenance, associated
with dyskeratosis congenita,6 and genes involved in DNA repair
associated with Fanconi anemia.7 Pathogenic mutations in these
pathways perturb cell homeostasis and lead ultimately to failure of
the bone marrow to produce a sufﬁcient amount of blood cells.
Based on the inheritance patterns of IBMFSs in multiplex families
and the segregation of mutated alleles in known IBMFS genes of
phenotypically affected family members, the disorders are
considered monogenic in the vast majority of patients.
A large proportion of IBMFSs are important cancer predisposi-
tion syndromes, with a particularly increased risk of myelodys-
plastic syndrome (MDS) and acute myeloid leukemia (AML).1, 2 In
particular, Fanconi anemia,8 Shwachman–Diamond syndrome,9
severe congenital neutropenia,10 and familial thrombocytopenia
with predisposition to MDS/AML11 were associated with the
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development of malignancies. There is an overlap of classical
IBMFSs and secondary MDS due to MDS-predisposing germline
mutations (e.g., RUNX1, ETV6, and GATA2-related disorders), as
patients with these mutations can present with MDS without any
additional features of IBMFSs.12 The risk of development of
cancers differs greatly between the various IBMFSs, and identiﬁca-
tion of the underlying etiology of marrow failure is imperative to
assess the need and type of cancer screening.2
Identifying the causal genotype in cases with IBMFSs is
challenging.13 In part, the challenge derives from a large number
of patients who cannot be classiﬁed into speciﬁc syndromic
diagnoses, in spite of having features highly suggestive of an
inherited disorder.14 To improve the efﬁciency of genetic testing,
utilization of comprehensive next generation sequencing panels
was shown to be successful. In a previous report from our group
using a panel of 72 genes, the genotype was elucidated in 59% of
the patients with clinically classiﬁed disorders, and 18% of the
patients with marrow failure who were not clinically classiﬁed into
one particular IBMFS.15
Copy number variants (CNVs, i.e. insertions and deletions of at
least 1 kilobasepairs) have been found as the underlying genetic
mutation in a variety of disorders. Speciﬁcally, neurocognitive
illnesses, such as autism spectrum disorders and schizophrenia,16
epilepsy,17 cerebral palsy,18 and congenital heart disease19, 20 were
found to be associated with this type of genetic alterations. Short
stature has also been associated with rare CNVs.21 Cases of IBMFSs
with pathogenic CNVs have been reported previously, most notably
in Diamond–Blackfan anemia22–24 but also in Fanconi anemia.25, 26
In particular, an association of these types of mutations with
neurodevelopmental delay22 and short stature23 has been sug-
gested in small series of patients with Diamond–Blackfan anemia.
Identiﬁcation of CNVs is not efﬁciently done through Sanger
sequencing and targeted next-generation gene panel sequen-
cing.27 Therefore, CNVs are often missed when a genome-wide
analysis, such as a single nucleotide polymorphism (SNP) array or
comparative genomic hybridization (CGH) array, is not per-
formed.28–30 The cost of these tests is relatively modest around
USD 300–400 per assay. In contrast, commercially available
targeted next-generation sequencing gene panels, used to detect
smaller aberrations of the genetic code, harbor costs of around
USD 1500–4000 per assay.15
The proportion of cases harboring pathogenic CNVs among
patients who have, or are suspected to have IBMFSs, and the
importance of ﬁnding such genetic lesions in this population is
unknown. The aims of this study were to determine the utility of
genome-wide microarray analysis to detect pathogenic CNVs, to
characterize the genetic lesions and phenotypes of patients with
CNVs, and to identify clinical features that might be associated
with CNVs. Since CNVs directly disrupt all or a large sequence of
the respective gene, and sometimes adjacent genomic regions, it
was hypothesized that patients with pathogenic CNVs would likely
have a more extensive clinical phenotype compared to
nucleotide-level mutations (i.e., single nucleotide variants and
small insertions/deletions).
RESULTS
Characteristics of the patients
Of the 451 patients enrolled in the Canadian Inherited Marrow
Failure Registry (CIMFR) from January 2001 to December 2014,
genetic test results were available for 323 (71.6%) patients.
Genetic testing was done at the discretion of the treating
physicians and/or as part of systematic genotyping of enrolled
patient into our research laboratory (YD). One hundred eighty of
the 323 patients (55.7%) were found to have causal mutations,
which included nucleotide-level mutations, CNVs, or both
(Supplementary Table 1). Four patients had insufﬁcient data to
determine the type of mutation, and they were excluded from
further analysis. Patients were diagnosed with a wide variety of
IBMFSs according to established criteria (Supplementary Table 2).
Nucleotide-level variant analysis
Among the group of 323 patients who had genetic testing, 303
patients (93.8%) underwent investigation for nucleotide-level
mutations by either Sanger sequencing, disease-speciﬁc next-
generation sequencing (NGS) panels, or by a comprehensive
research panel of 72, and later 77 IBMFS genes (ibmfNGS Panel).15
These genetic evaluations were undertaken either at our research
laboratory (YD), or accredited clinical laboratories. Causal
nucleotide-level mutations were found in 157 patients (51.8%,
Supplementary Table 3). These included 37 patients with small
indels involving 1–20 bp. The majority of unclassiﬁed patients had
undergone extensive genetic testing, which was negative.13–15
Genome-wide CNV analysis
Sixty-seven of 323 patients had genome-wide CNV analysis by
SNP/CGH arrays (20.7%). Of those, 39 were assessed in a research
laboratory (YD) and the rest in a clinical laboratory. The identiﬁed
median number of CNVs in the patients assessed in the research
laboratory was 141 (interquartile range 133–158) per patient.
Further ﬁltering identiﬁed a median of 65.5 (59–72) CNVs being
>1 kb with ﬁve or more probes and 5 (3–7) were found to be rare.
Finally, zero to four CNVs per patient were found to affect coding
regions in all but one patient. The latter was found to have a
signiﬁcantly higher number of rare CNVs, which might be due to
ethnical differences.
Of the 67 patients tested with genome-wide CNV analysis, 11
were found to harbor pathogenic CNVs, resulting in a detection
rate of 16.4%. Seven patients were identiﬁed with a monoallelic
CNV (four patients with Diamond-Blackfan anemia and one with
Potocki–Lupski syndrome, supernumerary ring chromosome
1 syndrome, and RUNX1-associated familial thrombocytopenia/
AML, each), one patient (with Fanconi anemia) harbored two
different compound-heterozygous CNVs, and three patients were
compound-heterozygous for a CNV and a nucleotide-level
mutation (one patient with dyskeratosis congenita and two
patients with Thrombocytopenia absent radius syndrome, respec-
tively). In four of 11 cases who were genotyped by SNP/CGH array,
genotyping was critical for establishing the diagnosis, as their
clinical phenotype was not explicit. The diagnoses in these cases
included PARN-associated dyskeratosis congenita (published
previously),31 RPL11- and RPL35a-associated Diamond-Blackfan
anemia, and Potocki–Lupski syndrome (Table 1).32
In addition to the 11 patients identiﬁed with genome-wide CNV
analysis, patients were also found to have pathogenic CNVs by
metaphase cytogenetics, multiplex ligation-dependent probe
ampliﬁcation assay, ﬂuorescence in-situ hybridization, DNA-
quantitative real-time PCR analysis, and Southern blotting
(Supplementary Table 3). Altogether, 19 patients were found to
harbor pathogenic CNVs in our study. The CNVs ranged from 5 kb
to 145.1 Mb in size (Table 1). The most common disease associated
with pathogenic CNVs in this population was Diamond–Blackfan
anemia, found in four of 35 genotyped patients (11.4%); followed
by thrombocytopenia absent radius syndrome (n = 3, 100%),
trisomy 8 syndrome (n = 3, 100%), and Fanconi anemia found in
two of 28 patients (7.1%). Four patients had compound
heterozygosity for a CNV and nucleotide-level mutations (Supple-
mentary Table 1).
Differences in clinical phenotypes between patients with CNVs
and nucleotide-level mutations
The clinical characteristics of patients who harbor pathogenic
CNVs or nucleotide-level mutations are shown in Table 2.
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Demographic data were similar among the groups. The age at
presentation and age at diagnosis were assessed where available,
which was the case in 17 and 19 patients harboring CNVs,
respectively, and 143 and 146 patients without CNVs, respectively.
There was no statistical difference between cases with CNVs and
cases with nucleotide-level mutations (Fig. 1).
To assess the potential effect of pathogenic CNV mutations on
hematological phenotype across the different types of IBMFSs, the
age at onset of severe cytopenias was assessed where this
information was available. No differences were found between
patients with CNVs (n = 17) and those without CNVs (n = 146)
(Fig. 2a). Similarly, the overall survival was not different between
the two groups (Fig. 2b).
The correlation of CNV mutations with the extent of involve-
ment of non-hematological organ systems was analyzed. Agree-
ment in assignment of non-hematological organ system
involvement between two evaluators was excellent (kappa =
0.87; 95%-CI 0.85–0.89). Patients with pathogenic CNVs were
found to have symptoms in signiﬁcantly more non-hematological
organ systems compared to patients with nucleotide-level
mutations (p = 0.0006; Fig. 3). Patients with CNVs were also found
to have a signiﬁcantly higher proportion of developmental delay
(p = 0.006) and short stature (p = 0.04) compared to patients with
nucleotide-level mutations (Fig. 4).
Since the above analyses included several syndromes with small
numbers of patients, a subgroup analysis of only IBMFSs with at
least ﬁve cases that included patients with CNVs, as well as
patients with nucleotide-level mutations, was performed. Patients
with Diamond–Blackfan anemia, Fanconi anemia, dyskeratosis
congenita, and familial thrombocytopenia/AML and MDS predis-
position syndromes due to RUNX1, ANKRD26 gene mutations, and
GATA2-associated MDS/AML met these criteria. Patients harboring
Table 1. Characteristics of the identiﬁed copy number alterations
Patient
number
Syndrome Gene/genomic region
(inheritance pattern)
HumanGenome19 coordinates or
cytogenetic location
Approximate
size of the CNV
Detection method
1# Diamond–Blackfan anemia RPL35a (AD) del(chr3:186,550,246–197,837,050)x1 11.3 Mb Array 1 and FISH
2# Diamond–Blackfan anemia RPS17 (AD) del(chr15:83,196,738–84,812,671)x1 1.6 Mb Array 2
3# Diamond–Blackfan anemia RPL5 (AD) del(chr1:92,932,837–94,018,138)x1 1.1 Mb Array 3
4# Diamond–Blackfan anemia RPL11 (AD) del(chr1:23,449,116–24,147,166)x1 698 kb Array 4
5 TAR syndrome Chr1q21.1 del(chr1:145,390,101–145,792,052)x1 402 kb Array 5
RBM8A (AR) c.−21G>A (chr1:145,507,646G>A) SNV
6 TAR syndrome Chr1q21.1 del(chr1:145,372,550–145,792,064)x1 420 kb Array 5
RBM8A (AR) c.−21G>A (chr1:145,507,646G>A) SNV
7 TAR syndrome Chr1q21.1 del(chr1:144,100,000–144,290,000)x1* 190 kb Quantitative PCR
RBM8A (AR) NA SNV
8 Trisomy 8 syndrome Chr8 (aneuploidy) dup(chr8) 145.1 Mb Cytogenetics and
FISH
9 Trisomy 8 syndrome Chr8 (aneuploidy) dup(chr8) 145.1 Mb Cytogenetics and
FISH
10 Trisomy 8 syndrome Chr8 (aneuploidy) dup(chr8) 145.1 Mb Cytogenetics and
FISH
11# Fanconi anemia FANCA (AR) FANCA deletion exon 31* 5 kb MLPA
FANCA deletion exons 4–29* 49 kb MLPA
12# Fanconi anemia FANCA (AR) del(chr16:89,799,574–89,847,471)x1 47.9 kb Array 2
del(chr16:89,824,684–89,869,755)x1 45 kb Array 2
13# Dyskeratosis congenita PARN (AR) del(chr16:14,658,272–14,679,880)x1 21.6 kb Array 5
c.1045C>T (chr16:14,676,047G>A) SNV
14# Familial
Thrombocytopenia/AML
RUNX1 (AD) del(chr21:34,965,815–36,781,907)x1 1.8 Mb‡ Array 6 and FISH
15 Pearson syndrome mitDNA
(mitochondrial)
del(mitDNA)* 6 kb Southern blot
16 SRC1 syndrome Chr1p13.1 +r(chr1:116,673,235–152,748,194) 36.1 Mb Array 7 and
cytogenetics
17 Wolf–Hirschhorn
syndrome
Chr4p der(4)t(4;8)(p16.3;p23.1)* 2.5 Mb(del),
9 Mb(dup)
Cytogenetics and
FISH
18 Jacobson syndrome 11q23 del(11)(q23.3)x1* 17Mb Cytogenetics
19 Potocki–Lupski syndrome 17p11.2 dup(chr17:16,778,108–18,252,450)x1 1.5 Mb Array 8 and FISH
#, patients included in the subset analysis; *, for methods without identiﬁcation of the exact breakpoint, the genomic locations were estimated as well as the
total size of the respective CNV; ‡, complex intrachromosomal rearrangement of chromosome 21 including a deletion involving the RUNX1 gene
AD autosomal dominant, AML acute myeloid leukemia, AR autosomal recessive, Array 1 Agilent 105 K Human Genome Oligonucleotide array, Array 2 Agilent
180 K Human Genome Oligonucleotide array, Array 3 GeneDx 180 K microarray v4, Array 4 Agilent Oligo Array – EmArray cyto 6000 custom design, Array 5
Affymetrix SNP Array 6.0, Array 6 CytoSure Syndrome Plus V2, Array 7 Roche NimbleGen 135 K oligonucleotide array, Array 8 Signature Genomic
SignatureChipWG Whole genome BAC array, FISH ﬂuorescence in-situ hybridization, MLPA Multiplex Ligation-dependent Probe Ampliﬁcation, NA not available,
SNV single nucleotide variant, SRC1 supernumerary ring chromosome 1, TAR thrombocytopenia absent radius
Copy number variants in inherited bone marrow failure
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whole or large segmental chromosome alterations that are
typically identiﬁed through metaphase cytogenetics and patients
with thrombocytopenia-absent radius syndrome who are typically
identiﬁed by combined sequencing and targeted copy number
analysis of the RBM8A gene were thus excluded. Patients included
in this sub-analysis were all identiﬁed by genome-wide CNV
analysis. This subgroup analysis revealed no differences between
patients with CNVs (n = 8) and nucleotide-level mutations (n = 81)
with regard to age at presentation, age at diagnosis, onset of
severe cytopenias, and overall survival (Supplementary Figs. 1 and 2).
However, similar to the whole group analysis, a signiﬁcantly higher
number of organ system involvement was found among cases
with CNVs compared to other types of mutations (p = 0.007).
Importantly, a signiﬁcantly higher incidence of developmental
delay (p = 0.04), and short stature (p = 0.02) was also found in the
subgroup analysis.
Finally, to further adjust for potential bias caused by unequal
distribution of syndromes with high or low number of organ system
involvement between the two genetic groups, the extent of non-
hematological organ system involvement was dichotomized. A trend
was seen towards more cases showing “extensive non-hematological
organ system involvement” for the speciﬁc syndromes with CNVs
(75%) compared to those without (39%) but the difference in
incidence did not reach statistical signiﬁcance (p = 0.07).
Table 2. Phenotypic characteristics of patients included in this study, sorted by cases with copy number variants (CNVs) and other mutations
Patients with CNVs Patients with other mutations p-value
(n= 19) (n= 157)
Sex (females, %) 7 (36.8%) 76 (48.4%) p= 0.5
Median age at presentation (IQR) 1 month (1–14) 5 months (1–41) p= 0.1
Median age at diagnosis (IQR) 14 months (2–78) 24 months (5–88.25) p= 0.2
Median age at last follow up (IQR) 12.6 years (6.5–16.7) 12.2 years (7–18) p= 0.6
Severe anemia (n, %) 9 (50%) 64 (46.4%) p= 0.8
NA (n) 1 19
Severe neutropenia (n, %) 5 (35.7%) 56 (41.8%) p= 0.8
NA (n) 5 23
Severe thrombocytopenia (n, %) 5 (31.3%) 18 (13.3%) p= 0.07
NA (n) 3 22
Severe aplastic anemia (n, %) 4 (21.1%) 33 (21%) p= 1.0
NA (n) 0 0
MDS/ AML (n, %) 5 (26.3%) 26 (16.7%) p= 0.3
NA (n) 0 1
Median number of non-hematological systems involved (IQR) 6 (3.75–8) 3 (1–5) p= 0.0006
Developmental delay (n, %) 11 (61.1%) 40 (27.4%) p= 0.006
NA (n) 1 11
Short stature (n, %) 12 (66.7%) 59 (40.1%) p= 0.04
NA (n) 1 10
CNV copy number variant, IQR inter-quartile range, NA data not available
Fig. 1 Analysis of clinical parameters comparing cases with CNVs vs. other mutations. a Age at presentation, color bars representing
corresponding median; b Age at diagnosis, color bars representing corresponding median
Copy number variants in inherited bone marrow failure
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DISCUSSION
Patients who present with bone marrow failure often cannot be
directly assigned to a speciﬁc syndromic and genetic diagnosis.
Our group and others showed that utilization of a comprehensive
nucleotide-level testing approach, that targets a large number of
known IBMFS genes in one next-generation sequencing panel,
have resulted in a high identiﬁcation rate of causal mutations with
sometimes unexpected genetic ﬁndings and amendment of
clinical diagnoses.15, 33 The present study shows that genome-
wide CNV analysis can reveal causal mutations in a substantial
number of patients with IBMFSs. Importantly, there was a
difference in non-hematological phenotypes in patients affected
with pathogenic CNVs compared to other types of mutations.
It is well known that patients with nucleotide-level mutations in
IBMFS genes can express hematological and non-hematological
symptoms as a consequence of a single gene mutation. It is
unknown what role CNVs play in IBMFSs as a group. The CIMFR
database offers the opportunity to assess a large cohort of
patients with IBMFSs in Canada. The registry data reﬂects the
unselected spectrum of diseases that get attention for workup of a
suspected IBMFS. The vast majority of patients was tested for
nucleotide-level mutations which revealed the causal genetic
germline mutation in about half of the patients. The current
analysis included 67 patients tested with a genome-wide
approach to identify CNVs. Of those, 16.4% harbored a pathogenic
CNV, which helped establish the genetic diagnosis in this patient
cohort.
Depending on the source of DNA, somatic mutations can
contaminate germline DNA sequences. The present study reduced
the risk of falsely identifying mutations as being germline by the
choice of sampled cells (see Methods section). Nevertheless, in a
small number of patients, peripheral blood myeloid cells were not
removed from the analysis and a possibility of somatic CNVs
cannot be completely excluded.
Previous studies assessed the extent of non-hematological
symptom manifestations by simply counting the number of
congenital defects.34 Since patients with IBMFSs may have
multiple defects in only one organ system (e.g., café-au-lait spots,
hyperpigmentation, and leukoplakia on the tongue and mucosal
surfaces), this approach does not provide information about the
potential biological links between a genetic lesion and the extent
of involvement of different organ systems. To overcome this
limitation, the symptoms were grouped by affected organ system
and the number of organ systems summed up. It was previously
unknown whether the presence of pathogenic CNVs increases the
risk of having more extensive organ system involvement. In this
study, patients with CNVs were found to be affected in
signiﬁcantly more non-hematological organ systems than those
with only nucleotide-level mutations. This was true for the whole
cohort including patients with structural chromosomal changes.
Interestingly, this association remained true for a subgroup of
IBMFSs where at least ﬁve patients were present with at least one
patient harboring a CNV excluding structural chromosomal
changes, rare IBMFSs, and IBMFSs where no CNVs were present.
Short stature and developmental delay are common features
among patients with IBMFSs. These complications are primarily
skeletal and neurological abnormalities, respectively. However,
both might be affected by defects in various other organ systems
(e.g., gastrointestinal, endocrine, cardiac etc.). We speculated that
larger mutations (i.e., CNVs) might affect several areas of the
genome, inﬂuencing several organ systems and therefore have an
effect on development and stature as markers for multisystem
involvement.
Furthermore, there is previously published data showing that
CNVs might be associated with a higher incidence of develop-
mental delay and short stature in patients with Diamond–Blackfan
anemia but no such association was seen in other IBMFSs.22, 23
Developmental delay and short stature were therefore analyzed
separately. Both were found to be more prevalent in patients with
CNVs in the whole cohort but also in the subgroup analysis of
patients with at least 5 patients and CNVs present. Due to the
sample size, it was difﬁcult to assess the impact of CNVs on
speciﬁc IBMFSs. Nevertheless, it is noteworthy that among
patients with Diamond-Blackfan anemia, three of four patients
with CNVs had growth retardation and three of four had
developmental delay (vs. 35.5% and 51.6% of patients without
CNVs, respectively).
Assessment of the age at presentation, age at diagnosis and age
at onset of severe cytopenias was performed. Most patients
Fig. 3 Analysis of non-hematological organ system involvement
comparing cases with CNVs vs. other mutations. Color bars
representing corresponding median
Fig. 2 Analysis of onset of hematological complications and survival
comparing cases with CNVs vs. other mutations. a Age at onset of
severe cytopenias; b Overall survival
Copy number variants in inherited bone marrow failure
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included in this study had this information available. In contrast to
the non hematological phenotype in the same patient group,
there was no difference in the age at presentation, age at
diagnosis and the age at onset of severe cytopenias between
patients harboring CNVs and those who do not have this type of
mutation. This might be due to the hematological phenotype
being inﬂuenced exclusively by the gene associated with the
IBMFS and not adjacent genomic areas. Since IBMFSs are rare, the
number of patients assessed might also have inﬂuenced the lack
of difference. Future studies with larger patient groups might
elucidate if there is a genuine difference in the mechanisms of the
hematological and non hematological phenotype in patients
affected with CNVs.
No attempt has previously been undertaken to assess the
impact of CNVs on the diagnostic investigative work-up of
patients who have signs of IBMFSs. Furthermore, for the entire
group of IBMFSs, there has not been a comparative assessment of
CNVs yet. To our knowledge, this is the largest study in which a
comprehensive analysis of various IBMFSs with known causal
genotypes has been conducted.
Our study has several limitations. First, although 19 patients with
CNVs is a relatively large number when rare disorders such as
IBMFSs are analyzed, larger studies are necessary to validate these
results. Speciﬁcally, the number of patients per IBMFS was too
small for intrasyndromic variation analysis. Another limitation is
that patients harboring compound-heterozygous and homozygous
mutations have been analyzed together in autosomal recessive
diseases. In such cases, the genotype severity was graded
according to the presumably most damaging lesion, i.e., CNVs. It
would be of interest to analyze these groups separately to assess
whether there are differences in cases with heterozygous,
homozygous and compound-heterozygous CNV mutations. In
addition, some mutations (e.g., nonsense or indel with frameshift)
can have a major impact on the pathophysiology of the disease by
either completely abrogating the translated protein or changing its
function. The impact of a variant on the function of the translated
protein was not assessed in this analysis. Similarly, some missense
mutations have major deleterious effects on protein function and
these mutations can cause a severe clinical phenotype. One such
example is the Hoyeraal-Hreidarsson syndrome associated with
TINF2 mutations.35 Further, IBMFS genes may vary in the degree of
essentiality and affect the phenotype in different ways. Last, it is
noteworthy that our approach to quantify organ system involve-
ment could not assess the impact of encountered defects on
morbidity and quality of life. Future methods that focus on these
questions should be developed.
The mechanisms for the encountered differences in CNVs
compared to other mutations could not be elucidated with this
study. CNVs could affect the phenotype of IBMFS patients by
either severely damaging the IBMFS protein itself or by affecting
additional genes surrounding the IBMFS gene locus. Future
research needs to evaluate what mechanism is underlying this
difference in phenotypes.
In summary, most patients with IBMFSs have nucleotide-level
mutations. However, an important proportion of patients harbor
pathogenic CNVs that are not efﬁciently detected by current
nucleotide-level testing methods. Therefore, genome-wide CNV
analysis should be considered in IBMFS cases where nucleotide-
level sequencing does not reveal the causal mutation or in cases
with autosomal recessive disorders where only one pathogenic
allele was found by nucleotide-level analysis. According to our
analysis this is true not only for Diamond–Blackfan anemia and
Fanconi anemia patients as suggested previously,22–26 but in
general for patients with suspected IBMFS. The costs associated
with this additional analysis are relatively modest. In urgent cases,
simultaneous investigation to reveal both, nucleotide-level muta-
tions and CNVs, should be considered. In this IBMFS cohort,
pathogenic CNVs were associated with more extensive non-
hematological organ system involvement, and a higher preva-
lence of developmental delay and short stature. Patients with
these clinical features should be assessed with CNV analysis early
in the evaluation of their disease.
METHODS
The Canadian inherited marrow failure registry
The Canadian Inherited Marrow Failure Registry (CIMFR) is a multicenter
prospective study, which was approved by the Research Ethics Boards of
all participating institutions. Individuals who fulﬁlled diagnostic criteria for
an IBMFS13 were recruited by pediatric hematologists and oncologists at
participating centers who care for >95% of the eligible pediatric IBMFS
population in Canada. Patients were enrolled in the study registry after
informed written consent was obtained from the patient or their guardian.
Eligibility criteria included evidence of chronic bone marrow failure in
addition to either a family history of an IBMFS, physical malformations,
presentation earlier than 1 year of age, or positive genetic testing for an
associated IBMFS gene. When possible, each case was assigned a speciﬁc
syndromic diagnosis by the participating center. Diagnoses were reviewed
centrally, and if necessary were adjusted based on published diagnostic
criteria of speciﬁc IBMFSs1, 3, 36, 37 after veriﬁcation with the respective
center. Cases that fulﬁlled the eligibility criteria, but did not meet the
clinical, laboratory and genetic diagnostic criteria for any known IBMFS
subtype were deﬁned as unclassiﬁed IBMFSs.14 Patients were excluded if
they were diagnosed with (i) acquired aplastic anemia (i.e., without the
above criteria for inherited bone marrow failure), (ii) de novo leukemia or
leukemia with an unclassiﬁed syndrome without preceding bone marrow
failure, or (iii) de novo myelodysplastic syndrome (MDS).
The current study included patients who had been enrolled in the CIMFR
from its inception in January 2001 until December 2014. Data available for
these patients until June 2015 were analyzed. Patient information at study
entry and at yearly follow-up was collected and included demographics,
Fig. 4 Analysis of speciﬁc organ system involvement comparing cases with CNVs vs. other mutations. a Developmental delay; b Short stature
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clinical symptoms, family history, physical malformations, laboratory tests,
diagnoses, genetic tests, imaging studies, treatment, and outcomes.
Next generation sequencing panel assay and Sanger sequencing
Genomic DNA from either bone marrow ﬁbroblasts, expanded peripheral
blood T-cells, or whole blood cells was extracted. Comprehensive testing
for 72 and 77 IBMFS genes respectively was done by an NGS IBMFS gene
panel using the HaloPlex Capture Kit (Agilent Technologies, Santa Clara,
CA) for DNA library preparation, and Illumina HiSeq 2500 platform for
sequencing, as described previously.15 Sanger sequencing was done as
previously described.13 Brieﬂy, targeted genes were analyzed by bidirec-
tional sequencing of individual exons and ﬂanking intronic regions after
PCR ampliﬁcation.
Genome-wide copy number variant analysis
For genome-wide CNV analysis, Affymetrix SNP6.0 array, Affymetrix Inc.,
Santa Clara, CA, was performed in our research laboratory (YD). To
minimize the possibility of detecting somatic CNVs, genomic DNA was
extracted from either bone marrow ﬁbroblasts, expanded peripheral blood
T-cells, or whole blood cells. The assay features 1.8 million genetic markers,
including more than 906,600 SNPs and more than 946,000 probes for
detection of CNVs. It was performed according to the manufacturer’s
instructions as previously reported.9 A subset of patients were analyzed
with other CNV arrays in one of two clinical laboratories: either the clinical
Cytogenetics laboratory at the Hospital for Sick Children (Toronto, Ontario,
Canada), or at Prevention Genetics (Marshﬁeld, Wisconsin, USA; Table 1
and Supplementary Table 4). In these cases, DNA from either phorbol
myristate acetate-stimulated lymphocytes or whole blood was extracted
and standard protocols were used for the assays and variant calling.
Three different types of CNV calling algorithms were used, namely
Birdsuite,38 iPattern,39 and Affymetrix Genotyping Console software. CNVs
that were more than 1 kb in size with ﬁve or more consecutive array
probes were selected. CNVs seen in 2 or 3 algorithms were considered as
stringent CNVs and were included in further analysis. CNVs were further
ﬁltered based on their occurrence in healthy control datasets that were
provided from The Center of Applied Genomics at the Hospital for Sick
Children. CNVs that were seen frequently in healthy controls were
removed and only rare CNVs were further prioritized based on (1) CNV
type (either deletion or gain), (2) region affected (coding or non-coding
regions of the gene), (3) CNVs affecting individual genes vs. multiple genes
and (4) known function of the gene in hematopoiesis.
Metaphase cytogenetics and ﬂuorescence in situ hybridization
Metaphase cytogenetic analysis and ﬂuorescence in situ hybridization
(FISH) were performed as previously described.40 In brief, for metaphase
cytogenetics, bone marrow or peripheral blood cells were cultured and
stopped in metaphase, stained and assessed by light-microscopy and
computer-based imaging techniques. FISH was performed with the locus-
speciﬁc probe according to clinical suspicion of a speciﬁc gene being
affected.
Grouping of cases according to genetic mutations
A genetic variant was called “causal” if the aberration fulﬁlled criteria of
being “most likely pathogenic” by in silico analysis15 or previously
described as “pathogenic” in public databases with a corresponding
clinical phenotype. Patients were grouped according to the causal
mutation having one of the following types of mutations: (1) CNVs
spanning at least 1 kb,41 (2) all other types of genetic mutations (i.e., single
nucleotide variants, and indels). All cases were grouped by the causal
genetic mutation type in dominantly inherited diseases. In diseases with
recessive inheritance, cases were assigned as follows: at least one
pathogenic CNV qualiﬁed for analysis in group 1; all other mutations in
group 2.
Assessment of hematological and non-hematological phenotype
To analyze the impact of different genetic aberrations on the disease
phenotype across all IBMFSs, age at presentation, age at diagnosis, age at
onset of severe cytopenias, and overall survival were analyzed. Age at
presentation was deﬁned as occurrence of any symptoms attributed to an
IBMFS of the hematopoietic or any other organ system. Age at diagnosis
was set as the age at which the speciﬁc IBMFS was diagnosed either
clinically or by genetic testing. Age at onset of severe cytopenias was the
age at which either of the following peripheral blood count values were
noted: (i) hemoglobin of <70 g/L and/or need for transfusions or other
treatments to increase the hemoglobin (e.g., steroids) for at least 3 months;
(ii) platelet count of <20 × 109/L and/or need for platelet transfusions for at
least 3 months; (iii) absolute neutrophil count <0.5 × 109/L and/or need for
granulocyte colony-stimulating factor treatment for at least 3 months.
Overall survival (OS) was deﬁned as the time from birth to last follow up
(censored) or death from any cause (event).
As various organ systems are affected in IBMFSs, the extent of non-
hematopoietic organ system involvement was evaluated. The absolute
number of organ systems affected was assessed by grouping clinical
symptoms into 17 different organ systems, and evaluating the number of
organ systems affected by at least one symptom (Supplementary Table 5).
Acquired symptoms and complications (e.g., acute infections) were
excluded. The involvement of each organ system was assigned by two
independent investigators (NW, MW). Agreement in assignment was
evaluated using the kappa statistic. Discordant ﬁndings were reviewed and
differences were resolved in a discussion among three investigators (NW,
MW, YD).
Cases were considered having “extensive non-hematological organ
system involvement” if non-hematological organ system involvement
exceeded the median found for the assigned IBMFS in the present study.
“Limited non-hematological organ system involvement” was deﬁned as
having an equal or lower number of organ systems affected compared to
the median for the speciﬁc syndrome.
Short stature was deﬁned as body height below the ﬁfth percentile for
age. Developmental delay was deﬁned as a delay in the attainment of
developmental milestones for young children and/ or inability to attend
regular school without special assistance for school-aged children.
Statistical analysis
Results were presented using descriptive statistics, including calculation of
median and inter-quartile ranges (IQR) for continuous variables, and
percentages for categorical variables. Fisher’s exact test was used to
compare dichotomous variables. Mann–Whitney U test was used to assess
for differences in continuous variables. Survival analysis and evaluation of
onset of severe cytopenias were performed with the Kaplan Meier estimate
and Mantel–Cox log-rank test. Two-tailed p < 0.05 was considered
statistically signiﬁcant. Statistical analysis was conducted through Graph-
pad Prism 6.0 h (La Jolla, California, USA).
Data availability
As many of the IBMFSs included in this study contain only small numbers
of individual patients, the risk of identifying single patients is high despite
avoidance of explicit identiﬁers. Therefore, the clinical data are not publicly
available due to them containing information that could compromise
research participant privacy/consent.
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